Codexis (NASDAQ:CDXS) will be releasing its earnings data after the market closes on Wednesday, March 7th. Analysts expect Codexis to post earnings of $0.06 per share for the quarter.
Shares of Codexis (CDXS) opened at $9.35 on Wednesday. The stock has a market capitalization of $439.96, a P/E ratio of -14.38 and a beta of -1.61. Codexis has a one year low of $3.85 and a one year high of $9.45.
A number of analysts have recently weighed in on the company. BidaskClub upgraded Codexis from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.50 price target on shares of Codexis in a research report on Tuesday, November 21st. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Codexis presently has an average rating of “Buy” and a consensus target price of $8.58.
Codexis Company Profile
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.